| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
2'-Hydroxychalcone (10-90 μM; 12-72 h) inhibited cell viability in a dose-dependent manner, with IC50 values of 37.74 μM and 34.26 μM for two breast cancer cell lines, MCF-7 and CMT-1211, respectively [1]. 2'-Hydroxychalcone (10-30 μM; 24 h) promoted the accumulation of autophagic vesicles in breast cancer cells [1]. 2'-Hydroxychalcone (30 μM; 24 h) induced autophagy-dependent apoptosis in breast cancer cells and increased the cleavage of caspase-3 and PARP [1]. 2′-Hydroxychalcone (10-30 μM; 24 h) significantly reduced the expression of p-IκB and p-NF-κBp65, and increased the levels of p-ERK and p-JNK [1]. 2'-Hydroxychalcone (30 μM; 12-24 hours) increases intracellular ROS levels and triggers endoplasmic reticulum stress in breast cancer cells [1].
|
|---|---|
| ln Vivo |
2'-Hydroxychalcone (20-60 mg/kg; intraperitoneal injection; every 2 days; 3 weeks) can show antitumor effects in vivo without causing obvious toxicity to vital organs [1].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: MCF-7 and CMT-1211 Tested Concentrations: 10 μM, 20 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM, and 90 μM Incubation Duration: 12 h, 24 h, 36 h, 48 h, 60 h, and 72 h Experimental Results: Suppressed cell viability in a dose-dependent manner. Western Blot Analysis[1] Cell Types: MCF-7 and CMT-1211 Tested Concentrations: 10 μM, 20 μM, 30 μM Incubation Duration: 24 h Experimental Results: Regulated MAPK/NF-κB signaling pathways and inhibited migration/invasion of breast cancer cells. Cell Autophagy Assay[1] Cell Types: MCF-7 and CMT-1211 Tested Concentrations: 10 μM, 20 μM, 30 μM Incubation Duration: 24 h Experimental Results: Induced autophagy and promoted autophagy flux in breast cancer cells. Apoptosis Analysis[1] Cell Types: MCF-7 and CMT-1211 Tested Concentrations: 30 μM Incubation Duration: 24 h Experimental Results: Induced autophagy-dependent apoptosis of breast cancer cells. |
| Animal Protocol |
Animal/Disease Models:Five-week-old Balb/C female mice injected with CMT-1211 cells[1]
Doses: 20 mg/kg, 40 mg/kg, 60 mg/kg Route of Administration: Intraperitoneal injection; every 2 days; 3 weeks Experimental Results: Suppressed tumor growth and metastasis in vivo. |
| ADME/Pharmacokinetics |
Metabolism / Metabolites
2p-Hydroxychalcone has known human metabolites that include 2p-Hydroxychalcone, 2p-hydroxy-glucuronide. |
| References |
|
| Additional Infomation |
2'-hydroxychalcone is a member of the class of chalcones that is trans-chalcone substituted by a hydroxy group at position 2'. It has a role as an anti-inflammatory agent. It is a member of phenols and a member of chalcones. It is functionally related to a trans-chalcone.
2'-Hydroxychalcone has been reported in Cryptocarya concinna with data available. |
| Molecular Formula |
C15H12O2
|
|---|---|
| Molecular Weight |
224.25
|
| Exact Mass |
224.084
|
| CAS # |
1214-47-7
|
| PubChem CID |
638276
|
| Appearance |
Solid powder
|
| Density |
1.191g/cm3
|
| Boiling Point |
396.6ºC at 760mmHg
|
| Melting Point |
86-88 °C(lit.)
|
| Flash Point |
169.4ºC
|
| Vapour Pressure |
7.4E-07mmHg at 25°C
|
| Index of Refraction |
1.653
|
| LogP |
3.288
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
17
|
| Complexity |
277
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C1=C([H])C([H])=C([H])C([H])=C1C(/C(/[H])=C(\[H])/C1C([H])=C([H])C([H])=C([H])C=1[H])=O
|
| InChi Key |
AETKQQBRKSELEL-ZHACJKMWSA-N
|
| InChi Code |
InChI=1S/C15H12O2/c16-14-9-5-4-8-13(14)15(17)11-10-12-6-2-1-3-7-12/h1-11,16H/b11-10+
|
| Chemical Name |
(E)-1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-one
|
| Synonyms |
2'-Hydroxychalcone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4593 mL | 22.2965 mL | 44.5931 mL | |
| 5 mM | 0.8919 mL | 4.4593 mL | 8.9186 mL | |
| 10 mM | 0.4459 mL | 2.2297 mL | 4.4593 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
